Women's Health Approved Deal Benchmarks — China (2026)
Median upfront of $286M with total deal values reaching $885M in China territory.
Median Upfront
$286M
Total Deal Value
$750M
Royalty Range
8.4%–14.3%
Territory Multiplier
0.12x
Understanding Women's Health Deal Benchmarks at Approved
Approved Women's Health licensing deals in China territory command a median upfront payment of $286M, with values ranging from $204M at the low end to $349M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the women's health therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Full Benchmark Data
Full Benchmark Table
Low, median, and high ranges for upfront payments, total deal values, and royalty rates.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Comparable Deals
See All Comparable Deals
View 0 comparable Women's Health transactions with upfront payments, total values, and deal structures.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Approved Women's Health deals in China territory?
More Expert Insights
Territory impact analysis, royalty negotiation strategies, and deal structure guidance.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Related Benchmarks
$5M upfront
Women's Health · Preclinical · China
$11M upfront
Women's Health · Phase 1 · China
$39M upfront
Women's Health · Phase 2 · China
$104M upfront
Women's Health · Phase 3 · China
$249M upfront
Oncology · Approved · China
$177M upfront
Neurology/CNS · Approved · China
$410M upfront
Immunology · Approved · China
$418M upfront
Metabolic/Obesity · Approved · China
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open Deal CalculatorCite This Data
Ambrosia Ventures. (2026). Women's Health Approved Deal Benchmarks — China (2026). Retrieved from https://calculator.ambrosiaventures.co/data/womens-health-approved-deals-china
<a href="https://calculator.ambrosiaventures.co/data/womens-health-approved-deals-china">Women's Health Approved Deal Benchmarks — China (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=womensHealth&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,900+ verified biopharma transactions. Updated monthly.